Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines

Tomoyuki Tano, Masato Okamoto, Shin Kan, Koh Ichi Nakashiro, Shigetaka Shimodaira, Naomi Yamashita, Yutaka Kawakami, Hiroyuki Hamakawa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Toll-like receptor 4 (TLR4) plays a significant role in cancer therapy as receptors of bacteria-derived immunotherapeutic agents such as OK-432, a streptococcal immunotherapeutic agent. In addition, recent reports demonstrated that TLRs, including TLR4, are also expressed in cancer cells as well as in immunocompetent cells. It is a problem in cancer therapy that the immunoadjuvant may activate survival signals such as nuclear factor (NF)-κB or mitogen-activated protein kinases (MAPKs) in cancer cells via TLRs. In the current study, we investigated responsiveness of human head and neck cancer cell lines against TLR4 ligands, OK-PSA, an active component of OK-432, and a lipopolysaccharide (LPS). Stimulation with LPS or OK-PSA resulted in the activation of NF-κB in these cell lines expressing TLR4 and MD-2 that is a significant coreceptor for TLR4 signaling. Interestingly, OK-PSA induced cell-growth inhibition, while LPS enhanced the proliferation of the cancer cells. OK-PSA induced NF-κB activation more slowly than that induced by LPS. In addition, phosphorylation of p38 MAPK by OK-PSA was only slight compared with that by LPS. OK-PSA also induced apoptosis of the cancer cells mediated by the activation of caspase 1, 3 and 8 in a p53-independent manner. These findings strongly suggest that active components of OK-432 may elicit anti-cancer effects via enhancing host immunity as well as via directly inducing the growth inhibition and apoptosis of head and neck cancer cells through TLR4 signal.

Original languageEnglish
Pages (from-to)678-685
Number of pages8
JournalOral Oncology
Volume48
Issue number8
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Picibanil
Toll-Like Receptor 4
Head and Neck Neoplasms
Apoptosis
Cell Line
Lipopolysaccharides
Growth
Neoplasms
Immunologic Adjuvants
Caspase 1
Caspase 8
p38 Mitogen-Activated Protein Kinases
human TLR4 protein
Mitogen-Activated Protein Kinases
Caspase 3
Immunity
Phosphorylation
Cell Proliferation
Ligands
Bacteria

Keywords

  • Apoptosis
  • Head and neck cancer cells
  • OK-432
  • Toll-like receptor 4

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. / Tano, Tomoyuki; Okamoto, Masato; Kan, Shin; Nakashiro, Koh Ichi; Shimodaira, Shigetaka; Yamashita, Naomi; Kawakami, Yutaka; Hamakawa, Hiroyuki.

In: Oral Oncology, Vol. 48, No. 8, 08.2012, p. 678-685.

Research output: Contribution to journalArticle

Tano, Tomoyuki ; Okamoto, Masato ; Kan, Shin ; Nakashiro, Koh Ichi ; Shimodaira, Shigetaka ; Yamashita, Naomi ; Kawakami, Yutaka ; Hamakawa, Hiroyuki. / Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. In: Oral Oncology. 2012 ; Vol. 48, No. 8. pp. 678-685.
@article{32d4fb2dd4194546aeddbf2cda493749,
title = "Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines",
abstract = "Toll-like receptor 4 (TLR4) plays a significant role in cancer therapy as receptors of bacteria-derived immunotherapeutic agents such as OK-432, a streptococcal immunotherapeutic agent. In addition, recent reports demonstrated that TLRs, including TLR4, are also expressed in cancer cells as well as in immunocompetent cells. It is a problem in cancer therapy that the immunoadjuvant may activate survival signals such as nuclear factor (NF)-κB or mitogen-activated protein kinases (MAPKs) in cancer cells via TLRs. In the current study, we investigated responsiveness of human head and neck cancer cell lines against TLR4 ligands, OK-PSA, an active component of OK-432, and a lipopolysaccharide (LPS). Stimulation with LPS or OK-PSA resulted in the activation of NF-κB in these cell lines expressing TLR4 and MD-2 that is a significant coreceptor for TLR4 signaling. Interestingly, OK-PSA induced cell-growth inhibition, while LPS enhanced the proliferation of the cancer cells. OK-PSA induced NF-κB activation more slowly than that induced by LPS. In addition, phosphorylation of p38 MAPK by OK-PSA was only slight compared with that by LPS. OK-PSA also induced apoptosis of the cancer cells mediated by the activation of caspase 1, 3 and 8 in a p53-independent manner. These findings strongly suggest that active components of OK-432 may elicit anti-cancer effects via enhancing host immunity as well as via directly inducing the growth inhibition and apoptosis of head and neck cancer cells through TLR4 signal.",
keywords = "Apoptosis, Head and neck cancer cells, OK-432, Toll-like receptor 4",
author = "Tomoyuki Tano and Masato Okamoto and Shin Kan and Nakashiro, {Koh Ichi} and Shigetaka Shimodaira and Naomi Yamashita and Yutaka Kawakami and Hiroyuki Hamakawa",
year = "2012",
month = "8",
doi = "10.1016/j.oraloncology.2012.02.005",
language = "English",
volume = "48",
pages = "678--685",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines

AU - Tano, Tomoyuki

AU - Okamoto, Masato

AU - Kan, Shin

AU - Nakashiro, Koh Ichi

AU - Shimodaira, Shigetaka

AU - Yamashita, Naomi

AU - Kawakami, Yutaka

AU - Hamakawa, Hiroyuki

PY - 2012/8

Y1 - 2012/8

N2 - Toll-like receptor 4 (TLR4) plays a significant role in cancer therapy as receptors of bacteria-derived immunotherapeutic agents such as OK-432, a streptococcal immunotherapeutic agent. In addition, recent reports demonstrated that TLRs, including TLR4, are also expressed in cancer cells as well as in immunocompetent cells. It is a problem in cancer therapy that the immunoadjuvant may activate survival signals such as nuclear factor (NF)-κB or mitogen-activated protein kinases (MAPKs) in cancer cells via TLRs. In the current study, we investigated responsiveness of human head and neck cancer cell lines against TLR4 ligands, OK-PSA, an active component of OK-432, and a lipopolysaccharide (LPS). Stimulation with LPS or OK-PSA resulted in the activation of NF-κB in these cell lines expressing TLR4 and MD-2 that is a significant coreceptor for TLR4 signaling. Interestingly, OK-PSA induced cell-growth inhibition, while LPS enhanced the proliferation of the cancer cells. OK-PSA induced NF-κB activation more slowly than that induced by LPS. In addition, phosphorylation of p38 MAPK by OK-PSA was only slight compared with that by LPS. OK-PSA also induced apoptosis of the cancer cells mediated by the activation of caspase 1, 3 and 8 in a p53-independent manner. These findings strongly suggest that active components of OK-432 may elicit anti-cancer effects via enhancing host immunity as well as via directly inducing the growth inhibition and apoptosis of head and neck cancer cells through TLR4 signal.

AB - Toll-like receptor 4 (TLR4) plays a significant role in cancer therapy as receptors of bacteria-derived immunotherapeutic agents such as OK-432, a streptococcal immunotherapeutic agent. In addition, recent reports demonstrated that TLRs, including TLR4, are also expressed in cancer cells as well as in immunocompetent cells. It is a problem in cancer therapy that the immunoadjuvant may activate survival signals such as nuclear factor (NF)-κB or mitogen-activated protein kinases (MAPKs) in cancer cells via TLRs. In the current study, we investigated responsiveness of human head and neck cancer cell lines against TLR4 ligands, OK-PSA, an active component of OK-432, and a lipopolysaccharide (LPS). Stimulation with LPS or OK-PSA resulted in the activation of NF-κB in these cell lines expressing TLR4 and MD-2 that is a significant coreceptor for TLR4 signaling. Interestingly, OK-PSA induced cell-growth inhibition, while LPS enhanced the proliferation of the cancer cells. OK-PSA induced NF-κB activation more slowly than that induced by LPS. In addition, phosphorylation of p38 MAPK by OK-PSA was only slight compared with that by LPS. OK-PSA also induced apoptosis of the cancer cells mediated by the activation of caspase 1, 3 and 8 in a p53-independent manner. These findings strongly suggest that active components of OK-432 may elicit anti-cancer effects via enhancing host immunity as well as via directly inducing the growth inhibition and apoptosis of head and neck cancer cells through TLR4 signal.

KW - Apoptosis

KW - Head and neck cancer cells

KW - OK-432

KW - Toll-like receptor 4

UR - http://www.scopus.com/inward/record.url?scp=84864416934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864416934&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2012.02.005

DO - 10.1016/j.oraloncology.2012.02.005

M3 - Article

C2 - 22387210

AN - SCOPUS:84864416934

VL - 48

SP - 678

EP - 685

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 8

ER -